Robust preclinical models of anti-CTLA-4 antibody therapy
- A robust treatment protocol in line with published literature data.
- Syngeneic tumor models - tumor cells are implanted into immunocompetent mice, to evaluate drug effects on the anti-tumor immune response in the presence of a functionally immunocompetent system.
- Anti-CTLA-4 responding & non-responding tumor models, including colon, breast, and unique bioluminescent glioblastoma cancer models